Biomea Fusion Inc

NASDAQ BMEA

Download Data

Biomea Fusion Inc Price to Operating Income Ratio (P/OI) on June 03, 2024: -2.87

Biomea Fusion Inc Price to Operating Income Ratio (P/OI) is -2.87 on June 03, 2024, a 74.87% change year over year. The price to operating income ratio compares the market price per share of a company's stock to its operating income per share. It is calculated by dividing the market capitalization by the operating income, divided by the number of outstanding shares. This ratio provides insights into the market's valuation of a company's operating income generation. A higher ratio suggests that investors are willing to pay a higher price for each unit of operating income, indicating positive market sentiment and expectations for future profitability.
  • Biomea Fusion Inc 52-week high Price to Operating Income Ratio (P/OI) is -2.15 on November 13, 2023, which is 25.01% above the current Price to Operating Income Ratio (P/OI).
  • Biomea Fusion Inc 52-week low Price to Operating Income Ratio (P/OI) is -12.71 on June 08, 2023, which is -343.10% below the current Price to Operating Income Ratio (P/OI).
  • Biomea Fusion Inc average Price to Operating Income Ratio (P/OI) for the last 52 weeks is -4.51.
NASDAQ: BMEA

Biomea Fusion Inc

CEO Mr. Thomas Andrew Butler
IPO Date April 16, 2021
Location United States
Headquarters 900 Middlefield Road, Redwood City, CA, United States, 94063
Employees 110
Sector Healthcare
Industry Biotechnology
Description

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Similar companies

EWTX

Edgewise Therapeutics Inc

NA

NA

HOWL

Werewolf Therapeutics Inc

NA

NA

CGEM

Cullinan Oncology LLC

NA

NA

DSGN

Design Therapeutics Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email